ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Luvadaxistat Study Results Did Not Meet Primary Endpoint americanpharmaceuticalreview
March 08, 2021Neurocrine Biosciences announced investigational drug luvadaxistat did not meet its primary endpoint in the Phase II INTERACT study in adults with negative symptoms of schizophrenia, as measured by the change from baseline on the PANSS NSFS at Day 84.
Pharma Sources Insight January 2025
